Outpatient parenteral antimicrobial therapy for patients with Enterococcus faecalis endocarditis using continuous infusion IV benzylpenicillin plus IV ceftriaxone.

IF 3.7 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2024-10-24 eCollection Date: 2024-10-01 DOI:10.1093/jacamr/dlae168
Simon Briggs, Eamon Duffy, Hasan Bhally, Matthew Broom, Patrick Campbell, Rebekah Lane, Stephen McBride, Genevieve Walls, Simon Dalton
{"title":"Outpatient parenteral antimicrobial therapy for patients with <i>Enterococcus faecalis</i> endocarditis using continuous infusion IV benzylpenicillin plus IV ceftriaxone.","authors":"Simon Briggs, Eamon Duffy, Hasan Bhally, Matthew Broom, Patrick Campbell, Rebekah Lane, Stephen McBride, Genevieve Walls, Simon Dalton","doi":"10.1093/jacamr/dlae168","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many patients with <i>Enterococcus faecalis</i> endocarditis are clinically stable and able to leave hospital before completing antibiotic treatment, but data are lacking regarding some outpatient treatment options.</p><p><strong>Objectives: </strong>To assess the outcomes for adults with <i>E. faecalis</i> endocarditis receiving outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion IV benzylpenicillin plus bolus/continuous infusion IV ceftriaxone.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed adults who received at least 2 weeks duration of OPAT for <i>E. faecalis</i> endocarditis with the above treatment regimen in the Auckland and Christchurch regions between July 2019 and September 2022.</p><p><strong>Results: </strong>Forty-four patients met inclusion criteria. Fifteen were female (34%). The median age was 80 (IQR 71.5 to 84) years. Twenty-two (50%) had prosthetic valve (PV), 15 (34%) native valve (NV), 3 (7%) NV and/or cardiac implantable electronic device (CIED) infection, 3 (7%) PV and/or CIED infection, and 1 (2%) repaired valve endocarditis. Patients received a median of 16.5 days inpatient and 28 days OPAT antibiotic treatment. The 12 month outcome was cure (<i>n</i> = 25; 57%), antibiotic suppression (<i>n</i> = 9; 20%), relapse (<i>n</i> = 2; 5%; both possible) or death (<i>n</i> = 8; 18%). Compared with a historical cohort treated with OPAT continuous infusion IV benzylpenicillin plus bolus IV gentamicin, there was no difference in the relapse rate.</p><p><strong>Conclusions: </strong>This study adds to the accumulating evidence supporting the treatment of <i>E. faecalis</i> endocarditis with OPAT continuous infusion IV benzylpenicillin plus bolus/continuous infusion IV ceftriaxone. This is an option for patients requiring further antibiotic treatment at the time of hospital discharge.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae168"},"PeriodicalIF":3.7000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503647/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Many patients with Enterococcus faecalis endocarditis are clinically stable and able to leave hospital before completing antibiotic treatment, but data are lacking regarding some outpatient treatment options.

Objectives: To assess the outcomes for adults with E. faecalis endocarditis receiving outpatient parenteral antimicrobial therapy (OPAT) with continuous infusion IV benzylpenicillin plus bolus/continuous infusion IV ceftriaxone.

Patients and methods: We retrospectively reviewed adults who received at least 2 weeks duration of OPAT for E. faecalis endocarditis with the above treatment regimen in the Auckland and Christchurch regions between July 2019 and September 2022.

Results: Forty-four patients met inclusion criteria. Fifteen were female (34%). The median age was 80 (IQR 71.5 to 84) years. Twenty-two (50%) had prosthetic valve (PV), 15 (34%) native valve (NV), 3 (7%) NV and/or cardiac implantable electronic device (CIED) infection, 3 (7%) PV and/or CIED infection, and 1 (2%) repaired valve endocarditis. Patients received a median of 16.5 days inpatient and 28 days OPAT antibiotic treatment. The 12 month outcome was cure (n = 25; 57%), antibiotic suppression (n = 9; 20%), relapse (n = 2; 5%; both possible) or death (n = 8; 18%). Compared with a historical cohort treated with OPAT continuous infusion IV benzylpenicillin plus bolus IV gentamicin, there was no difference in the relapse rate.

Conclusions: This study adds to the accumulating evidence supporting the treatment of E. faecalis endocarditis with OPAT continuous infusion IV benzylpenicillin plus bolus/continuous infusion IV ceftriaxone. This is an option for patients requiring further antibiotic treatment at the time of hospital discharge.

对患有粪肠球菌性心内膜炎的患者采用持续输注静脉注射苄青霉素加静脉注射头孢曲松的门诊肠外抗菌疗法。
背景:许多粪肠球菌心内膜炎患者临床症状稳定,可以在完成抗生素治疗前离开医院,但缺乏有关一些门诊治疗方案的数据:目的:评估成人粪肠球菌性心内膜炎患者接受门诊肠外抗菌治疗(OPAT),即持续输注静脉滴注苄青霉素加栓剂/持续输注静脉滴注头孢曲松的疗效:我们回顾性研究了2019年7月至2022年9月期间奥克兰和基督城地区因粪肠球菌心内膜炎接受上述治疗方案的OPAT治疗至少2周的成人患者:44名患者符合纳入标准。其中15人为女性(34%)。中位年龄为80岁(IQR为71.5至84岁)。22人(50%)患有人工瓣膜(PV),15人(34%)患有原发瓣膜(NV),3人(7%)患有NV和/或心脏植入电子装置(CIED)感染,3人(7%)患有PV和/或CIED感染,1人(2%)患有修复过的瓣膜心内膜炎。患者接受了中位数为 16.5 天的住院治疗和 28 天的 OPAT 抗生素治疗。12 个月的治疗结果为治愈(25 人;57%)、抗生素抑制(9 人;20%)、复发(2 人;5%;均有可能)或死亡(8 人;18%)。与使用 OPAT 持续输注静脉注射苄青霉素加静脉注射庆大霉素治疗的历史队列相比,复发率没有差异:这项研究补充了支持用OPAT持续输注静脉滴注苄青霉素加静注/持续输注静脉滴注头孢曲松治疗粪肠球菌性心内膜炎的证据。对于出院时需要进一步接受抗生素治疗的患者来说,这不失为一种选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信